Earlier initialization of highly active antiretroviral therapy is associated with long-term survival and is cost-effective: findings from a deterministic model of a 10-year Ugandan cohort.

Journal of acquired immune deficiency syndromes (1999)

Volumn 61, Issue 3, 2012, Pages 364-369

  Mills, Fergal P ^a   Ford, Nathan ^b   Nachega, Jean B ^b   Bansback, Nicholas ^b   Nosyk, Bohdan ^b   Yaya, Sanni ^b   Mills, Edward J ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; MORTALITY; STATISTICAL MODEL; UGANDA;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG COSTS; HIV INFECTIONS; HUMANS; MODELS, ECONOMIC; UGANDA;

EID: 85027947617     PISSN: None     EISSN: 19447884     Source Type: Journal    
DOI: None     Document Type: Article

References (0)